Prospective, randomized, open-label,clinical trial comparing the effects of amlodipine monotherapy and irbesartan/amlodipine combination on blood pressure, endothelial function and makers for obesity/oxidative stress/chronic kidney diseases
Not Applicable
- Conditions
- Hypertension
- Registration Number
- JPRN-UMIN000011727
- Lead Sponsor
- ational Defense Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Allergy against 2) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits. 3) End stage renal disease 4) Subjects whose doctor in charge do not agree to join the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood pressure (On visit/Home monitoring) Flow-mediated vasodilation in forearm Heparin-releasable EC-SOD levels 12 weeks after administration
- Secondary Outcome Measures
Name Time Method Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), early-staged kidney diseases (microalbuminuria) 12 weeks after administration